BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19011338)

  • 1. [Relative dose intensity of FOLFOX4 regimen].
    Shouji D; Matsusaka S; Watanabe C; Suenaga M; Shinozaki E; Matsuda M; Kuboki K; Ogura M; Ichimura T; Keisho C; Mizunuma N; Hatake K
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1895-900. PubMed ID: 19011338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].
    Suenaga M; Nishina T; Hyodo I; Munakata M; Koizumi W; Mishima H; Sato A; Mizunuma N; Hatake K
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):255-60. PubMed ID: 18281761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Compliance with FOLFOX4 for Stage III colon cancer in the adjuvant setting].
    Okazaki S; Sugawara K; Hashizume E; Abe M; Hagiwara M; Aiso T; Shirahata Y; Chin M; Suzuki A; Kuriya Y
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):59-63. PubMed ID: 24423953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
    Ohnishi T; Kanoh T; Tono T; Danno K; Watanabe A; Nakamura H; Tsukao Y; Inatome J; Kim T; Kagara N; Taniguchi H; Kimura Y; Nakano Y; Monden T; Imaoka S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2554-6. PubMed ID: 21224637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
    Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
    Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
    Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
    Matsuda M; Matsusaka S; Kuboki Y; Itimura T; Ogura M; Suenaga M; Syouji D; Watanabe C; Chin K; Mizunuma N; Hatake K
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):461-6. PubMed ID: 18347395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
    Goldberg RM; Tabah-Fisch I; Bleiberg H; de Gramont A; Tournigand C; Andre T; Rothenberg ML; Green E; Sargent DJ
    J Clin Oncol; 2006 Sep; 24(25):4085-91. PubMed ID: 16943526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [FOLFOX4 regimen versus DP(O)F regimen for advanced gastric cancer].
    Wu F; Zhang HG; Ran FW; Zhang XR; Shi YK
    Ai Zheng; 2008 Apr; 27(4):413-7. PubMed ID: 18423129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
    Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
    Shimizu T; Satoh T; Tamura K; Ozaki T; Okamoto I; Fukuoka M; Nakagawa K
    Int J Clin Oncol; 2007 Jun; 12(3):218-23. PubMed ID: 17566846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
    Zhang XL; Shi HJ; Cui SZ; Tang YQ; Ba MC
    Eur J Surg Oncol; 2011 Jun; 37(6):466-72. PubMed ID: 21414740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.